ClinConnect ClinConnect Logo
Search / Trial NCT01792362

Evaluation of Anti-mullerian Hormone(AMH) Levels as a Predictive Factor of Response to Weight Loss Treatment in Obese Infertile Women With Poly Cystic Ovary(PCOS)

Launched by ROYAN INSTITUTE · Feb 13, 2013

Trial Information

Current as of August 25, 2025

Completed

Keywords

Anti Mullerian Hormone (Amh) Level, Poly Cystic Ovarian Syndrome Obese Infertility Weight Loss Diet

ClinConnect Summary

The study population comprised of all obese infertile PCOS patients aged 20-40 years which underwent 3 months weight loss diet in royan institute, Tehran Iran.

The study is conducted over 12 wk energy restriction. All subjects have the same dietary protocol. At baseline, week 12 the levels of AMH,Follicular Stimulating Hormone (FSH), Lutienizing Hormone(LH),Prolactin (PRL), androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices is calculated. The laboratory tests are determined by radioimmunoassay...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • - 1- diagnosis of PCOS, according to the Rotterdam Consensus Workshop Group, by 2 of the following 3 criteria: menstrual irregularity (cycle length\<26 d or \>31 d or variation between consecutive cycles of \>3 d); clinical (hirsutism assessed by a Ferriman-Gallwey score \> 8) or biochemical \[free androgen index (FAI) \> 5.4 or testosterone_1.4 nmol/L\] hyperandrogenism; or positive ultrasound presentation of polycystic ovaries by transvaginal scan.
  • 2- Age between 18 -40
  • Exclusion Criteria:
  • - 1. Body mass index (BMI; in kg/m2) \< 30, 2. Type 2 diabetes mellitus and related endocrinopathic disorders \[identified by assessment of thyroid-stimulating hormone (TSH), prolactin, and 17_hydroxyprogesterone\].
  • 3. Regular exercise activities during the study. 4. Cases of alcoholism and smoking. 5. The use of endocrine hormonal treatment or insulin-sensitizing agents is not permitted during either phase of the study, and the use of oral contraceptives is not permitted during of the study. Subjects are required to cease taking oral contraceptives 4 wk and hormonal treatment or insulin-sensitizing agents 2 wk before commencement of the short-term study phase.

About Royan Institute

The Royan Institute is a leading research organization dedicated to advancing the fields of reproductive health, stem cell biology, and regenerative medicine. Established to promote scientific innovation and clinical applications, the Institute focuses on translating cutting-edge research into therapeutic solutions. With a strong commitment to ethical practices and collaboration, Royan Institute conducts rigorous clinical trials aimed at improving patient outcomes and enhancing healthcare practices globally. Through its multidisciplinary approach and state-of-the-art facilities, the Institute strives to push the boundaries of medical science and contribute significantly to the understanding and treatment of complex health issues.

Locations

Tehran, , Iran, Islamic Republic Of

Patients applied

0 patients applied

Trial Officials

Hamid Gourabi, PhD

Study Chair

Head of Royan Institute

Ashraf Moini, MD

Study Director

Department of Endocrinology and Female Infertility, Reproductive Biomedicine Center, Royan institute for Reproductive Biomedicine, ACECR, Tehran, Iran

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials